RT Journal Article
SR Electronic
T1 Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.29.23287906
DO 10.1101/2023.03.29.23287906
A1 Chapman, Lloyd AC
A1 Aubry, Maite
A1 Maset, Noémie
A1 Russell, Timothy W
A1 Knock, Edward S
A1 Lees, John A
A1 Mallet, Henri-Pierre
A1 Cao-Lormeau, Van-Mai
A1 Kucharski, Adam J
YR 2023
UL http://medrxiv.org/content/early/2023/03/29/2023.03.29.23287906.abstract
AB Estimation of the impact of vaccination and non-pharmaceutical interventions (NPIs) on COVID-19 incidence is complicated by several factors, including the successive emergence of SARS-CoV-2 variants of concern and changing population immunity resulting from vaccination and previous infection. We developed an age-structured multi-strain COVID-19 transmission model framework that could estimate the impact of vaccination and NPIs while accounting for these factors. We applied this approach to French Polynesia, which unlike many countries experienced multiple large COVID-19 waves from multiple variants over the course of the pandemic, interspersed with periods of elimination. We estimated that the vaccination programme averted 54.3% (95% CI 54.0-54.6%) of the 6840 hospitalisations and 60.2% (95% CI 59.9–60.5%) of the 1280 hospital deaths that would have occurred in a baseline scenario without any vaccination up to May 2022. Vaccination also averted an estimated 28.4% (95% CI 28.2-28.7%) of 193,000 symptomatic cases in the baseline scenario. We estimated the booster campaign contributed 3.4%, 2.9% and 3.3% to overall reductions in cases, hospitalisations and hospital deaths respectively. Our results suggested that removing, or altering the timings of, the lockdowns during the first two waves had non-linear effects on overall incidence owing to the resulting effect on accumulation of population immunity. Our estimates of vaccination and booster impact differ from those for other countries due to differences in age structure, previous exposure levels and timing of variant introduction relative to vaccination, emphasising the importance of detailed analysis that accounts for these factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLACC and AJK are supported by funding from the National Institute for Health and Care Research (NIHR200908) and Wellcome Trust (206250/Z/17/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Secondary data analysis of routinely collected COVID-19 data from French Polynesia was approved by the London School of Hygiene and Tropical Medicine Observational Research Ethics Committee (ref 28129).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and code used in the analysis is available online at https://github.com/LloydChapman/covid_multi_strain https://github.com/LloydChapman/covid_multi_strain